10/567,472

=> d ibib abs hitstr 1-13

ANSWER 1 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2006:817544 CAPLUS

DOCUMENT NUMBER:

145:230788

TITLE:

Process for producing [1,4'-bipiperidine]-1'-carbonyl

chloride or its hydrochloride salt

INVENTOR (S):

Laitinen, Ilpo

PATENT ASSIGNEE(S):

Fermion Oy, Finland PCT Int. Appl., 12pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

SOURCE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

I	PATENT	KIN	ס	DATE			APPL	ICAT	ION I	NO.		Di	ATE				
V	NO 2006	 08494	40		A1	-	2006	0817	1	WO 2	 006-:	FI32			2	 0060:	206
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
							ID,										
		ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
		MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,
		SG,	SK,	SL,	SM,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,
•		VN,	YU,	ZA,	ZM,	ZW							·	•	•	•	•
	RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	ĒE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,
		ıs,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,
							GN,										
							NA,									-	-
					RU,				•	-	•	•	-	-	•	•	
PRIORI	PRIORITY APPLN. INFO.:					•			1	US 2	005-	6505	35P	1	P 20	0050	208
OTHER	SOURCE	(S):			CASI	REAC	T 14	5:230									
GT	THER SOURCE(S):																

$$N - CO$$

- AB A process was disclosed for the preparation of [1,4']bipiperidinyl-1' -carbonyl chloride (I) or its hydrochloride salt using methylene chloride as a solvent in the reaction of 4-piperidinopiperidine with phosgene and removing the reaction solvent by using an addnl. distillation solvent to raise the distillation temperature I was further reacted with 7-ethyl-10hydroxycamptothecin to form irinotecan hydrochloride, an antitumor alkaloid.
- IT 97682-44-5P, Irinotecan

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; process for the preparation

[1,4'-bipiperidine]-1'-carbonyl

chloride or its hydrochloride salt an intermediate for the synthesis of the antitumor alkaloid irinotecan)

RN 97682-44-5 CAPLUS

[1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-CN tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT 86639-52-3, 7-Ethyl-10-hydroxycamptothecin

RL: RCT (Reactant); RACT (Reactant or reagent)

(process for the preparation [1,4'-bipiperidine]-1'-carbonyl chloride or its hydrochloride salt an intermediate for the synthesis of the antitumor alkaloid irinotecan)

RN 86639-52-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT:

4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2006:792754 CAPLUS

DOCUMENT NUMBER:

145:230787

TITLE:

Process for the manufacturing of 7-ethyl-10-

hydroxycamptothecin

Laitinen, Ilpo

PATENT ASSIGNEE(S):

Fermion Oy, Finland

SOURCE:

PCT Int. Appl., 13pp.

CODEN: PIXXD2

DOCUMENT TYPE:

INVENTOR(S):

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATEI	PATENT NO.						DATE		1	APPL:	ICAT:	ON 1	10.		D	ATE	
		- ·				-		- -		 -		- -	- -	- -			
WO 20	0060	822	79		A1		2006	0810	ı	NO 20	006-1	7134			20	00602	206
Ţ	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	ВG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KN,	ΚP,	KR,
		KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
	MZ, NA, NO				NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,
		SG,	SK,	SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	ŪĠ,	US,	UΖ,	VC,
	SG, SK, SI VN, YU, ZA			ZA,	ZM,	ZW											
I	RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,
		IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,
							GN,										
		GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,
		KG,	KZ,	MD,	RU,	TJ,	TM										
PRIORITY A	RIORITY APPLN. INFO.:								Ţ	JS 20	005-6	55017	75P	1	2 (00502	207
OTHER SOU	THER SOURCE(S):				CASI	REAC	T 14!	5:230	787								
GI																	

IT 97682-44-5P, Irinotecan

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for manufacturing of 7-ethyl-10-hydroxycamptothecins)

RN 97682-44-5 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:151109 CAPLUS

DOCUMENT NUMBER: 144:233239

TITLE: An improved process for the preparation of irinotecan

hydrochloride trihydrate

INVENTOR(S): Vishnukant, B.; Purohit, Prashant; Paparao, K.;

Veereshapa

PATENT ASSIGNEE(S): Shilpa Medicare Limited, India

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT	PATENT NO.								APPL	ICAT:	ION 1	. OI		D	ATE	
WO 200	60162	03		A1	-	2006	0216	1	WO 2	004-	IB26:	26		20	0040	809
W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
	CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
	-	GH,	-	-												
	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NZ,														
	ŢJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
RW	: AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR.	GB,	GR,	HU,	ΙE,
		LU,	•	•	-											
	•	GA,		•	•		•	•	•	•	•	•	•	•		•
	-	MZ,	•					•				•			-	-
	•	ΤJ,	•		•	•	•		•	•	•	•	•	•	•	•
PRIORITY AF	•	•						1	WO 2	004-	IB26	26		20	00408	809
OTHER SOURC				CAS	REAC	T 14	4:23	3239								

AB An improved process was disclosed for the preparation of irinotecan hydrochloride trihydrate of enhanced yield and purity and comprised reacting 1-chlorocarbonyl-4-piperidinopiperidine hydrochloride with 7-ethyl-10-hydroxycamptothecin to obtain crude irinotecan (I) which was subsequently purified by solvent treatment, obtaining purified irinotecan which was converted into irinotecan hydrochloride trihydrate. This invention also relates to a report of 1-chlorocarbonyl-4piperidinopiperidine hydrochloride and a process for its preparation IT 97682-44-5P, Irinotecan RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (improved process for preparation of irinotecan hydrochloride trihydrate) RN97682-44-5 CAPLUS CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

IT 86639-52-3P, 7-Ethyl-10-hydroxycamptothecin RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (improved process for preparation of irinotecan hydrochloride trihydrate) RN86639-52-3 CAPLUS

CN1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

2005:1291999 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 144:23039

TITLE: Process to prepare camptothecin derivatives and novel

intermediate and compounds thereof

INVENTOR (S): Naidu, Ragina

Phytogen Life Sciences Inc., Can. U.S. Pat. Appl. Publ., 30 pp. PATENT ASSIGNEE(S): SOURCE:

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
DATE
       PATENT NO.
                                    KIND
                                              DATE
                                                               APPLICATION NO.
                                    ----
                                                               ______
       US 2005272757
                                     A1
                                              20051208
                                                               US 2004-861097
                                                                                                 20040604
                                                                                                20050603
       WO 2005117881
                                     A1
                                              20051215
                                                               WO 2005-US19700
                  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
                  CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
                  GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
                  LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
                  NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
            RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                                               US 2004-861097
                                                                                            A 20040604
                                    CASREACT 144:23039; MARPAT 144:23039
OTHER SOURCE(S):
GI
```

AB New processes are disclosed for the preparation of derivs. of camptothecin (I), such as, irinotecan and topotecan, as well as new intermediates and related compds.

IT 97682-44-5P, Irinotecan

RL: SPN (Synthetic preparation); PREP (Preparation) (claimed compound; process for the preparation of camptothecin derivs.)

RN 97682-44-5 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

IT 86639-52-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(claimed reactant; process for the preparation of camptothecin derivs.)

RN 86639-52-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,

4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1262080 CAPLUS

DOCUMENT NUMBER: 144:6956

TITLE: Process to prepare camptothecin derivatives

INVENTOR(S): Naidu, Ragina

PATENT ASSIGNEE(S): Phytogen Life Sciences Inc., Can:

SOURCE: U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005267141	A1	20051201	US 2004-857170	20040528

```
20051215
                                            WO 2005-US18793
                                                                    20050527
    WO 2005117879
                          A1
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
            MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                            US 2004-857170
                                                                A 20040528
                         CASREACT 144:6956; MARPAT 144:6956
OTHER SOURCE(S):
GΙ
```

AB A process is provided for the preparation of camptothecin derivs., such as irinotecan, in a one-pot operation by treating the starting material I (wherein each of the ring atoms may be carbon, or any one, two, or three of the ring atoms may be N; Ra, Rb, Rc are the same or different and independently represent one or more optional non-hydrogen substituent on each of the rings A, B, C) with R1R2NH (R1, R2 are the same or different and independently represent organic groups) to give II. Thus, 4-piperidinopiperidine was treated with phosgene in CH2Cl2 containing N,N-diisopropylethylamine followed by addition of SN-38 to give 94% irinotecan after workup.

IT 97682-44-5P, Irinotecan

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process to prepare camptothecin derivs.)

RN 97682-44-5 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

IT 86639-52-3, Sn-38

RL: RCT (Reactant); RACT (Reactant or reagent) (process to prepare camptothecin derivs.)

RN 86639-52-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2005:182668 CAPLUS

DOCUMENT NUMBER:

142:280341

TITLE:

Method of manufacturing of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin

(irinotecan base) by the esterification of

7-ethyl-10-hydroxycamptothecin with

1-chlorocarbonyl-4-piperidinopiperidine hydrochloride

in the presence of 4-dimethylaminopyridine

INVENTOR(S):

Dobrovolny, Petr

PATENT ASSIGNEE(S):

Pliva-Lachema A. S., Czech Rep.

SOURCE:

PCT Int. Appl., 11 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
APPLICATION NO.
                                                                                                    DATE
       PATENT NO.
                                     KIND
                                               DATE
                                                                                                    _____
                                     ----
                                                _____
                                                                 ______
                                                                 WO 2004-CZ50
                                                                                                    20040824
       WO 2005019223
                                      A1
                                                20050303
                   AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

                   SN, TD, TG
       AU 2004266752
                                                20050303
                                                                 AU 2004-266752
                                                                                                    20040824
                                      A1
                                                20060607
                                                                 EP 2004-762302
                                                                                                    20040824
       EP 1664054
                                      A1
                   AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
       US 2006199961
                                      Α1
                                                20060907
                                                                 US 2006-567472
                                                                                                    20060207
PRIORITY APPLN. INFO.:
                                                                 CZ 2003-2305
                                                                                                    20030826
                                                                                               W
                                                                 WO 2004-CZ50
                                                                                                    20040824
OTHER SOURCE(S):
                                     CASREACT 142:280341
       7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (i.e.,
       irinotecan base) is prepared in high yield and selectivity by the
       esterification of 7-ethyl-10-hydroxycamptothecin with 1-chlorocarbonyl-4-
       piperidinopiperidine hydrochloride in a polar aprotic solvent in the
       presence of 4-dimethylaminopyridine.
IT
       86639-52-3
       RL: RCT (Reactant); RACT (Reactant or reagent)
            (method of manufacturing of 7-ethyl-10-[4-(1-piperidino)-1-
            piperidino]carbonyloxycamptothecin (irinotecan base) by the
            esterification of 7-ethyl-10-hydroxycamptothecin with
            1-chlorocarbonyl-4-piperidinopiperidine hydrochloride)
RN
       86639-52-3 CAPLUS
CN
       1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,
       4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)
```

Absolute stereochemistry. Rotation (+).

IT 97682-44-5P, Irinotecan
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (method of manufacturing of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan base) by the esterification of 7-ethyl-10-hydroxycamptothecin with 1-chlorocarbonyl-4-piperidinopiperidine hydrochloride)
RN 97682-44-5 CAPLUS

[1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-CN tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT: THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN L7

ACCESSION NUMBER:

2002:658068 CAPLUS

DOCUMENT NUMBER:

137:201293

TITLE: INVENTOR(S): Method of synthesizing camptothecin-relating compounds Ogawa, Takanori; Nishiyama, Hiroyuki; Uchida, Miyuki;

Sawada, Seigo

PATENT ASSIGNEE(S):

Kabushiki Kaisha Yakult Honsha, Japan

PCT Int. Appl., 89 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	
WO 2002066416	A1 20020829	WO 2002-JP1538	
W: AE, AG,	AL, AM, AT, AU, AZ,	BA, BB, BG, BR, BY,	BZ, CA, CH, CN,
CO, CR, C	CU, CZ, DE, DK, DM,	DZ, EC, EE, ES, FI,	GB, GD, GE, GH,
GM, HR, I	HU, ID, IL, IN, IS,	JP, KE, KG, KP, KR,	KZ, LC, LK, LR,
LS, LT,	LU, LV, MA, MD, MG,	MK, MN, MW, MX, MZ,	NO, NZ, OM, PH,
PL, PT, 1	RO, RU, SD, SE, SG,	SI, SK, SL, TJ, TM,	TN, TR, TT, TZ,
UA, UG, U	JS, UZ, VN, YU, ZA,	ZM, ZW	
RW: GH, GM, 1	KE, LS, MW, MZ, SD,	SL, SZ, TZ, UG, ZM,	ZW, AT, BE, CH,
		GR, IE, IT, LU, MC,	
BF, BJ, (CF, CG, CI, CM, GA,	GN, GQ, GW, ML, MR,	NE, SN, TD, TG
		CA 2002-2437702	
		EE 2003-373	
EP 1378505	A1 20040107	EP 2002-703874	20020221
R: AT, BE, 0	CH, DE, DK, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, MC, PT,
IE, SI, I	LT, LV, FI, RO, MK,	CY, AL, TR	
		CN 2002-805323	
NZ 527615	A 20041224	NZ 2002-527615	20020221

		•		*		
BG 108031	Α	20050430	BG	2003-108031		20030725
ZA 2003006223	A	20040603	$z_{\mathbf{A}}$	2003-6223		20030812
NO 2003003579	A	20031010	NO	2003-3579		20030813
NZ 534374	Α	20041224	NZ	2003-534374		20030814
US 2004106830	A 1	20040603	US	2003-467987		20031218
US 7126000	B2	20061024				
PRIORITY APPLN. INFO.:			JP	2001-45430	Α	20010221
		•	JP	2001-309322	Α	20011005
			JP	2001-309332	Α	20011005
			WO	2002-JP1538	W	20020221
	~~~~			43 D D 3 M 4 3 M 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	`	

OTHER SOURCE(S):

CASREACT 137:201293; MARPAT 137:201293

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

2'-Amino-5'-hydroxypropiophenone (I) corresponding to the AB cycle moiety AB of the camptothecin (CPT) skeleton and a tricyclic ketone, namely (S)-4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)trione (II) corresponding to the CDE cycle moiety thereof can be efficiently produced and thus CPT and its derivs. can be stably supplied by a practically usable total synthesis to more efficiently provide camptothecin (CPT), which is a starting compound for irinotecan hydrochloride, namely 7-ethyl-10-[4-(1-piperidino)-1piperidino]carbonyloxycamptothecin hydrochloride trihydrate, and various camptothecin derivs. Thus, benzylation of 2-nitro-5-hydroxybenzaldehyde by benzyl chloride in the presence of K2CO3 in DMF at 60° for 20 h gave 94% 5-benzyloxy-2-nitrobenzaldehyde which went addition reaction with vinylmagnesium bromide in THF at 3-10° for 1 h to give 84.0% 1-(5-benzyloxy-2-nitrophenyl)-2-propen-1-ol (VIII). Oxidation of VIII with MnO2 in CHCl3 at 25° for 15 h gave 91% 1-(5-benzyloxy-2nitrophenyl)-1-oxo-2-propene which was hydrogenated over 10% Pd-C in EtOAc under H atmospheric for 13 h to give 81% I. K2OsO4.2H2O and (DHQD)2PYR were added to an aqueous solution of K3Fe(CN)6, K2CO3, and MeSO2NH2 and stirred at .apprx.5° for 1 h, followed by adding 4-ethyl-8-methoxy-6-(trimethylsilyl)-1H-pyrano[3,4-c]pyridine, and the resulting mixture was stirred at 5° for 20 h, treated with sodium sulfite, and stirred at 5° for 30 min for asym. dihydroxylation to give a diol (III) (95%) which was oxidized by iodine and K2CO3 in aqueous methanol at 40° for 48 h to give a lactone (IV; R = TMS) (88%). Iodination of IV (R = TMS) by iodine and CF3CO2Ag in CH2Cl2 at room temperature for 16.5 h gave IV (R = iodo) (97%) which underwent carbonylation by CO in the presence of Pd(OAc)2 and K2CO3 in 1-propanol at  $60^{\circ}$  for 18 to give an ester IV (R = n-PrO2C) (70%). Demethylation of IV (R = n-PrO2C) by treatment with Me3SiCl and NaI in MeCN at room temperature for 3 h gave a keto lactone, namely 4-ethyl-3,4,7,8-tetrahydro-4-hydroxy-3,8-dioxo-1H-pyrano[3,4-c]pyridine-6carboxylic acid Pr ester (V) (95%) which was cyclocondensed with tert-Bu acrylate in the presence of K2CO3 in DMSO at 50° for 20 min to give a tricyclic compound (VI) (77%). VI was heated with a mixture of CF3CO2H and PhMe at 110° for 100 min to give 77% II which was cyclocondensed with I in a 1:1 mixture of AcOH and toluene in the presence of p-toluenesulfonic acid monohydrate at 100° for 18 h to give SN-38 (VII; R1= H). VII (R1= H) was converted into irinotecan hydrochloride, VII.HCl (R1 = Q).

IT 97682-44-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of camptothecin-relating compds. such as irinotecan hydrochloride and intermediates thereof)

10/567,472

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT 86639-52-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP

(Preparation); RACT (Reactant or reagent)

(preparation of camptothecin-relating compds. such as irinotecan

hydrochloride and intermediates thereof)

RN 86639-52-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,

4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

REFERENCE COUNT:

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

7

ACCESSION NUMBER:

2001:713182 CAPLUS

DOCUMENT NUMBER:

135:262261

TITLE:

Preparation and antitumor activity of polyglutamic

acid-camptothecin conjugates

INVENTOR(S):

Bhatt, Rama; De Vries, Peter; Klein, J. Peter; Lewis,

Robert A.; Singer, Jack W.; Tulinsky, John

PATENT ASSIGNEE(S):

Cell Therapeutics, Inc., USA

SOURCE:

PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO						DATE		*	APPL	ICAT	ION	NO.		D	ATE	
			75		A2					WO 2	001-	US85	53		2	0010	319
	2001																
	. W:			-							-	-	-	-	-	-	-
		CZ,	DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,
	•	IS,	JP,	KΕ,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,
		MK,	MN,	MW,	MX,	NO,	ΝZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,
		TJ,	TM,	TR,	TT,	UA,	ŬĠ,	US,	UZ,	VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,
					TJ,												
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZW,	ΑT,	BE,	CH,	CY,
							GB,										
		•		-	-		•				-	-	-	-	-	•	٠.
CA	BJ, CF, C CA 2402643				ΑA		2001									0010	319
	2001																
	1267																
							ES,										
			•	-	-		RO,	-	•		-	,	,	,	,	,	,
,TP	2003		-		-		2003					5684	71		2	0010	319
	2117						2003										
	2001															0010	
	2001															0020	
	2002				А		2003	121/							_	0020	
PRIORITY	I APP	· ИП	TNFO	. :							000-					0000	
OTHER SO	אוופרב	(2) .			марі	ידעכ	135.	26221		wO 2	001-	US85.	53	1	₩ 2	0010	319

OTHER SOURCE(S): MARPAT 135:262261

Methods for the preparation of polyglutamic acid-therapeutic agent conjugates are disclosed. The compds. show antitumor activity. Thus, 20(S)-camptothecin was allowed to react with N-(tertbutoxycarbonyl)glycine in DMF solution in the presence of 4-dimethylaminopyridine followed by the addition of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The product, 20-O-(N-(tert-butoxycarbonyl)glycyl)camptothecin, was deprotected with CF3CO2H to give 20-O-(glycyl) camptothecintrifluoroacetic acid salt which was then treated with poly-(L-glutamic acid). The conjugate, polyglutamate-glycinecamptothecin showed high antitumor activity.

86639-52-3, SN 38 ΙT

RL: RCT (Reactant); RACT (Reactant or reagent) (preparation and antitumor activity of polyglutamic acid-camptothecin conjugates)

RN 86639-52-3 CAPLUS

1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, CN 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

IT 97682-44-5DP, Irinotecan, polyglutamic acid conjugates

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antitumor activity of polyglutamic acid-camptothecin conjugates)

97682-44-5 CAPLUS RN

[1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-CN tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2001:701089 CAPLUS

DOCUMENT NUMBER:

136:369880

TITLE: AUTHOR(S): Improved method for the synthesis of Irinotecan Li, Yuyan; You, Qidong; Li, Zhiyu; Wang, Hua

CORPORATE SOURCE:

Department of Medicinal Chemistry, China

Pharmaceutical University, Nanjing, 210009, Peop. Rep. China

SOURCE:

Zhongguo Yaowu Huaxue Zazhi (2001), 11(4), 238-240

CODEN: ZYHZEF; ISSN: 1005-0108

PUBLISHER:

Zhongguo Yaowu Huaxue Zazhi Bianjibu

DOCUMENT TYPE: LANGUAGE:

Journal Chinese

OTHER SOURCE(S): CASREACT 136:369880

Irinotecan was synthesized by alkylation camptothecin with propionaldehyde in water-glacial acetic acid in the presence of FeSO4 7H2O and H2SO4, oxidization with H2O2 at 80° for 3 h, rearrangement in dioxane-acetonitrile-water (25:50:8, volume/volume) in the presence of H2SO4 under illumination for 15 min to obtain 7-ethyl-10-hydroxycamptothecin; further acylation with 4-(1-piperidyl)piperidine-1-carbonylchloride, giving the product with overall yield 21%.

IT 86639-52-3P, 7-Ethyl-10-hydroxycamptothecin RL: RCT (Reactant); SPN (Synthetic preparation); PREP

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (improved method for the synthesis of Irinotecan)

RN 86639-52-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT 97682-44-5P, Irinotecan

RL: SPN (Synthetic preparation); PREP (Preparation) (improved method for the synthesis of Irinotecan)

RN 97682-44-5 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:48724 CAPLUS

DOCUMENT NUMBER: 130:125257

TITLE: Synthesis of and intermediates for camptothecins

INVENTOR(S): Curran, Dennis P.; Bom, David PATENT ASSIGNEE(S): University of Pittsburgh, USA

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE: Patent English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PA'	PATENT NO.					D :	DATE		1	APPI	LICAT	ION I	NO.		D	ATE	
WO	9901	 456			A1	_	 1999	0114	1	 WO 1	 L998 - 1	JS13	941		1	 9980'	702
	W:	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,
		DK,	EE,	ES,	FI,	GB,	GE,	GH,	GM,	GW,	HR,	HU,	ID,	IL,	IS,	JP,	KE,
		KG,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	MW,
		MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТĴ,	TM,	TR,
		TT,	UA,	UG,	UZ,	VN,	YU,	ZW					-	-	•		
	RW:	GH,	GM,	KE,	LS,	MW,	SD,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,	ES,
											PT,						
		CM,	GA,	GN,	ML,	MR,	NE,	SN,	TD,	TG							
US	6252	079			B1		2001	0626	1	US 1	1997-8	38609	93		1	9970	702
AU	9884	761			A1		1999	0125		L UA	1998-8	3476	1		1	9980'	702
PRIORIT	Y APP	LN.	INFO	. :					. 1	US 1	1997-8	3860	93		A 1	9970	702
	RIORIII AIIIM. IMIO								1	US 1	1993-8	35190	0		B2 1	9930	630
						1	US 1	1995-4	1367	99	:	B2 1	9950	508			
									1	WO 1	.998 <b>-</b> t	JS139	941	1	W 1	9980'	702
OFFITTE OF	TIPD COLIDGE (C)									2.52							

OTHER SOURCE(S): CASREACT 130:125257; MARPAT 130:125257

GΙ

AB Camptothecin analogs, such as I [R = H, alkoxy, N containing heterocyclyl, such as piperidinyl; R1 = allyl, propargyl, benzyl, alkyl], were prepared via a novel [4 + 1] radical annulation of the corresponding isonitriles II with pyridinones III [X = Br, iodo] for use as topoisomerase inhibitors. Thus, (+)-irinotecan I [R = piperidinyl, R1 = Et] was prepd in 31% yield by cyclization of isonitrile II [R = piperidinyl] with pyridinone III [R1 = Et, X = iodo] in the presence of hexadimethylditin in benzene. The prepared compds were tested for topoisomerase I inhibiting activity and

cytotoxic activity against HL-60 human promyelocytic leukemic cells and against 833K human teratocarcinoma cells.

IT 86639-52-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthesis of camptothecins via radical cyclization for use as topoisomerase inhibitors)

RN 86639-52-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT 97682-44-5P, (+)-Irinotecan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of camptothecins via radical cyclization for use as topoisomerase inhibitors)

RN 97682-44-5 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS 3 REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 11 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN L7

ACCESSION NUMBER: 1996:701701 CAPLUS

DOCUMENT NUMBER:

125:329101

TITLE:

Novel intermediates and process for the manufacture of

camptothecin derivatives (CPT-11) and related

compounds

INVENTOR(S):

Henegar, Kevin E.; Sih, John C.

PATENT ASSIGNEE(S):

Upjohn Co., USA

SOURCE:

PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.						DATE						ION I				ATE	
	9631				A1		1996										9960	
	W:	AL,	AM,	AT;	AU,	AZ,	BB,	BG,	BR,	ВУ	ζ,	CA,	CH,	CN,	CZ,	DE,	DK,	EE,
		ES,	FI,	GB,	GE,	HU,	IS,	JP,	KE,	KG	3,	KP,	KR,	KZ,	LK,	LR,	LT,	LU,
				-		-	MX,	-	-		-					-		
		SK,	•	•	•	•	•	•	•		•	•	•	•	•		•	•
	RW:			MW.	SD.	SZ.	UG,	AT.	BE.	CH	ł.	DE.	DK.	ES.	FI.	FR.	GB.	GR.
							PT,											
		MR,			,	,	,	,	,		•		,		,	,	,	
TW	4387				В		2001	0607		TW	19	96-	8510	3680		1	9960	327
	11768						2002						1176				9960	
	.2214				AA		1996	1010					2214				9960	
	96552				A1		1996	1023					5527				9960	
	7171				B2		2000					-	JJL,	•		_	,,,,,	101
	8352				A1		1998			EP	19	96-	9124	68		1	9960	401
	8352				B1		2002					-		•		_	,,,,,,	
21	R:		BE.	CH.			ES,		GB.	GE	₹.	TT.	T.T.	TiII.	NT.	SE	MC	PΨ.
					LV,		20,	,	UD,	٠.	٠,	,	,	_0,	112,	J_,	,	,
CN	11810		01,	,	A,		1998	0506		CN	19	96-	1931	3.8		1	9960	401
	11000				В		2003									_	2200	
	11503				T2		1999			JΡ	19	96-	5303	56		1	9960	401
	21649				C2		2001						1186				9960	
	22489				E		2002			AT	19	96-	9124	68			9960	
	8352				·T		2003						9124				9960	
	2183				ጥጓ		2003						9124				9960	
	18644				B1		2004						3226				9960	
	1865				B1		2004						3553				9960	
	9602				A		1998						2747				9960	
	61214				A		2000			US	19	97-	2302	45			9971	
	97046			•	A		1997			NO	1.9	97-	4608				9971	
	32048				B1		2005											
	10094				A1		2003			нк	19	98-	1104	39		1	9980	904
	62359				B1		2001						5110				0000	
	64448				B1		2002						6872				0001	
	14340				A		2003						1030				0030	
	14340				Α		2003						1030				0030	
	14340				Α		2003			CN	20	03-	1030	99		2	0030	
	14340				Α		2003						1031				0030	
	1055				A1		2006			HK	20	03-	1074	20			0031	
	20050		08		A		1997					05-		- •			0050	
PRIORIT													4196	43	;			
										WO	19	96-	US41	 63	-	 1	9960	401
										US	19	97-	US41	 4 5	j	43 1	9971	002
															-			

OTHER SOURCE(S):

MARPAT 125:329101

GI

$$R^3$$
 $OR^2$ 
 $R^4$ 
 $OR^5$ 
 $R^5$ 
 $R^5$ 
 $R^5$ 
 $R^6$ 
 $R^6$ 

Preparation of novel intermediates, e.g. pyridines I (R1 = alkyl, cycloalkyl, AB alkenyl, aryl; R2 = alkyl, cycloalkyl, alkenyl, aryl; R3 = Cl, alkyl-, cycloalkyl-, alkenyl-, aryl-ester; R4 = alkyl, cycloalkyl, aryl; R4 = independently H, alkyl, aryl), and procedures for the synthesis of camptothecin derivs., e.g. irinotecan, and related compds., e.g. mappicine, were disclosed. Thus, I [R1 = Me, R2 = benzyl, R3 = CO2(CH2)CH3, R4 = Et, R5 = H] was prepared in several steps starting from citrazinic acid and was further converted to known camptothecin intermediate (II) via another series of steps.

86639-52-3P IT

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (novel intermediates and process for the manufacture of camptothecin derivs. and related compds.)

86639-52-3 CAPLUS RN

1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, CN 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT 97682-44-5P

> RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(novel intermediates and process for the manufacture of camptothecin derivs. and related compds.)

RN 97682-44-5 CAPLUS

[1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-CN tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

L7 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

1991:583643 CAPLUS

DOCUMENT NUMBER:

115:183643

TITLE:

Synthesis and antitumor activity of 20(S)-camptothecin

derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin Sawada, Seigo; Okajima, Satoru; Aiyama, Ritsuo;

Sawada, Seigo; Okajima, Satoru; Aiyama, Ritsuo; Nokata, Kenichiro; Furuta, Tomio; Yokokura, Teruo; Sugino, Eiichi; Yamaguchi, Kentaro; Miyasaka, Tadashi Yakult Inst. Microbiol. Res., Kunitachi, 186, Japan Chemical & Pharmaceutical Bulletin (1991), 39(6),

CORPORATE SOURCE:

SOURCE:

AUTHOR (S):

1446-54

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE:

LANGUAGE:

Journal English

Ι

GI

AB Novel 36 derivs. bonding the phenolic hydroxyl group of 7-ethyl-10-hydroxycamptothecin with diamines through a monocarbamate linkage, e.g. I (R = lower alkyl, R1 = Me2NCH2CH2, Et2NCH2CH2, RR1N = substituted piperazino, aminopiperidino) were synthesized and their antitumor activity was evaluated in vivo. The derivs. were soluble in water as their HCl salts with the E lactone ring intact and exhibited significant antitumor activity. I (RR1N = 4-piperidinopiperidino) showed excellent activity against L1210 leukemia and other murine tumors. The

structure of its hydrochloride trihydrate was determined by spectroscopic and crystallog. methods.

IT 97682-44-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antitumor activity of)

RN 97682-44-5 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT 86639-52-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction with phosgene and chlorocarbonyldiamines)

RN 86639-52-3 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

10/567,472

DOCUMENT NUMBER: 103:88119

TITLE: Camptothecin derivatives

PATENT ASSIGNEE(S): Yakult Honsha Co., Ltd., Japan Jpn. Kokai Tokkyo Koho, 8 pp. SOURCE:

CODEN: JKXXAF

DOCUMENT TYPE: Patent LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

·					
PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
				-	
JP 60019790	A2	19850131	JP 1983-126946		19830714
JP 03004077	B4	19910122			
US 4604463	Α	19860805	US 1984-627980		19840705
CA 1235415	A1	19880419	CA 1984-458228		19840705
EP 137145	A1	19850417	EP 1984-108257		19840713
EP 137145	B1	19880427			
R: AT, BE, CH,	DE, FR	, GB, IT, LI	, LU, NL, SE		
AT 33839	E	19880515	AT 1984-108257		19840713
PRIORITY APPLN. INFO.:			JP 1983-126946	Α	19830714
			EP 1984-108257	Α	19840713
OTHER SOURCE(S):	CASREA	CT 103:88119	; MARPAT 103:88119		

AB Twenty camptothecin derivs. I [R = H, alkyl; R1 = Cl, NR2R3 (R2, R3 = H, (un) substituted alkyl; R2 and R3 may form a heterocyclic)] were prepared as anticarbinogens or their intermediates (no data). Thus, 400  $\mu L$  COCl2 dimer was decomposed in the presence of active C and the resulting COC12 fed to a mixture of 500 mg 7-ethyl-10-hydroxycamptothecin and 2 mL Et3N in dioxane 0.5 h at room temperature to give 97.4% I (R = Et, R1 = C1). IT 86639-52-3

Ι

RL: RCT (Reactant); RACT (Reactant or reagent)

(chloroformylation of)

RN86639-52-3 CAPLUS

1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, . CN 4,11-diethyl-4,9-dihydroxy-, (4S)- (9CI) (CA INDEX NAME)

IT 97682-44-5P

RN 97682-44-5 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

## => d his

(FILE 'HOME' ENTERED AT 10:04:49 ON 25 OCT 2006)

FILE 'CAPLUS' ENTERED AT 10:07:01 ON 25 OCT 2006

L5 33 S L1/PREP L6 65 S L4/RCT L7 13 S L5 AND L6

# => d 11 YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

- L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
- RN 97682-44-5 REGISTRY
- ED Entered STN: 18 Aug 1985
- CN [1,4'-Bipiperidine]-l'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

- CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline, [1,4'-bipiperidine]-1'-carboxylic acid deriv.
- CN [1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, (S)-

## OTHER NAMES:

- CN (+)-Irinotecan
- CN Irinotecan
- CN Irinotecan lactone
- FS STEREOSEARCH
- MF C33 H38 N4 O6
- CI COM
- SR CA
- LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).

## **PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

- 1783 REFERENCES IN FILE CA (1907 TO DATE)
- 46 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA 1795 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l2 L2 HAS NO ANSWERS L2 STR

Structure attributes must be viewed using STN Express query preparation.

=>

=> d ibib abs hitstr 1-2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2005:182668 CAPLUS DOCUMENT NUMBER: 142:280341 TITLE: Method of manufacturing of 7-ethyl-10-[4-(1piperidino) -1-piperidino] carbonyloxycamptothecin (irinotecan base) by the esterification of 7-ethyl-10-hydroxycamptothecin with 1-chlorocarbonyl-4-piperidinopiperidine hydrochloride in the presence of 4dimethylaminopyridine INVENTOR (S): Dobrovolny, Petr PATENT ASSIGNEE(S): Pliva-Lachema A. S., Czech Rep. SOURCE: PCT Int. Appl., 11 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. DATE KIND DATE APPLICATION NO. -----_ - - _ 2005019223

A1 20050303 WO 2004-CZ50

20040824

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG WO 2005019223 A1 20050303 WO 2004-CZ50 20040824 AU 2004-266752 AU 2004266752 Α1 20050303 20040824 EP 1664054 20060607 A1 EP 2004-762302 20040824 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR US 2006199961 20060907 A1 US 2006-567472 20060207 PRIORITY APPLN. INFO.: CZ 2003-2305 A 20030826 WO 2004-CZ50 W 20040824 CASREACT 142:280341 OTHER SOURCE(S): 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (i.e., irinotecan base) is prepared in high yield and selectivity by the esterification of 7-ethyl-10-hydroxycamptothecin with 1-chlorocarbonyl-4piperidinopiperidine hydrochloride in a polar aprotic solvent in the presence of 4-dimethylaminopyridine. IT 97682-44-5P, Irinotecan RL: SPN (Synthetic preparation); PREP (Preparation) (method of manufacturing of 7-ethyl-10-[4-(1-piperidino)-1piperidino]carbonyloxycamptothecin (irinotecan base) by the

esterification of 7-ethyl-10-hydroxycamptothecin with 1-chlorocarbonyl-4-piperidinopiperidine hydrochloride)

[1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-

tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-

Absolute stereochemistry. Rotation (+).

b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

97682-44-5 CAPLUS

RN

CN

REFERENCE COUNT: THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2001:713182 CAPLUS

DOCUMENT NUMBER:

135:262261

TITLE:

Preparation and antitumor activity of polyglutamic

acid-camptothecin conjugates

INVENTOR(S):

Bhatt, Rama; De Vries, Peter; Klein, J. Peter; Lewis,

Robert A.; Singer, Jack W.; Tulinsky, John Cell Therapeutics, Inc., USA PCT Int. Appl., 81 pp.

PATENT ASSIGNEE(S):

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	TENT	NO.			KIN			<b>-</b>			ICAT					ATE	
	2001 2001				A2		2001	0927								0010	319
	W:	CZ, IS, MK, TJ,	DE, JP, MN, TM,	DK, KE, MW, TR,	EE, KG, MX,	ES, KP, NO, UA,	FI, KR, NZ,	GB, KZ, PL,	GD, LC, PT,	GE, LK, RO,	BR, GH, LR, RU, YU,	GM, LS, SD,	HR, LT, SE,	HU, LU, SG,	ID, LV, SI,	IL, MD, SK,	IN, MG, SL,
	RW:	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	TZ, LU, MR,	MC,	NL,	PT,	SE,		
ΑU	2402 2001 1267	643 0475:	13		AA A5	;	2001 2001	0927 1003	2	CA 2	001-: 001-	24026 4751	643 3		20	0010	319
	R:	AT, IE,	BE, SI,	CH, LT,	DE, LV,	DK, FI,	ES, RO,	FR, MK,	GB, CY,	GR, AL,	IT, TR	LI,	LU,	NL,	SE,	MC,	PT,
SI	JP 2003527443 T2 SI 21172 C BR 2001009272 A			C		2003	1031		SI 20	001-2	2002	1		20	00103	319	
NO	20020	00442	21		Α		2002	1115	1	10 20	001-3 002-4 002-7	1421			20	00103	916

PRIORITY APPLN. INFO.:

US 2000-190429P

20000317

WO 2001-US8553

20010319

OTHER SOURCE(S): MARPAT 135:262261

AB Methods for the preparation of polyglutamic acid-therapeutic agent conjugates are disclosed. The compds. show antitumor activity. Thus, 20(S)-camptothecin was allowed to react with N-(tert-butoxycarbonyl)glycine in DMF solution in the presence of 4-dimethylaminopyridine followed by the addition of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The product, 20-O-(N-(tert-butoxycarbonyl)glycyl)camptothecin, was deprotected with CF3CO2H to give 20-O-(glycyl)camptothecintrifluoroacetic acid salt which was then treated with poly-(L-glutamic acid). The conjugate, polyglutamate-glycine-camptothecin showed high antitumor activity.

IT 97682-44-5DP. Tripotecan, polyglutamic acid conjugates

IT 97682-44-5DP, Irinotecan, polyglutamic acid conjugates
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antitumor activity of polyglutamic acid-camptothecin conjugates)

RN 97682-44-5 CAPLUS

CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

=> d his

(FILE 'HOME' ENTERED AT 10:23:44 ON 25 OCT 2006)

FILE 'REGISTRY' ENTERED AT 10:23:56 ON 25 OCT 2006
L1 1 S IRINOTECAN/CN

FILE 'CAPLUS' ENTERED AT 10:24:31 ON 25 OCT 2006

L2 33 S L1/PREP

L3 2439 S 4-DIMETHYLAMINOPYRIDINE

L4 2 S L2 AND L3